Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_assertion type Assertion NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_head.
- NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_assertion description "[The 5-year survival rates were 57% for esophageal cancer patients with HER2 amplification compared with 32% without, but the difference in overall survival was not significant (P�=�.37).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_provenance.
- NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_assertion evidence source_evidence_literature NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_provenance.
- NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_assertion SIO_000772 21267790 NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_provenance.
- NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_assertion wasDerivedFrom befree-2016 NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_provenance.
- NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_assertion wasGeneratedBy ECO_0000203 NP867818.RAUFpWpbK7w2dvBPwA9nmlJMcG5Tq67tLmGYVs1w7nhXw130_provenance.